D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 129 SEK -1.9% Market Closed
Market Cap: 2.1B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Devyser Diagnostics AB
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Devyser Diagnostics AB
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
D
Devyser Diagnostics AB
STO:DVYSR
Accrued Liabilities
kr20m
CAGR 3-Years
38%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Accrued Liabilities
kr86.4m
CAGR 3-Years
21%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Accrued Liabilities
kr190m
CAGR 3-Years
15%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BioArctic AB
STO:BIOA B
Accrued Liabilities
kr43m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Devyser Diagnostics AB
Glance View

Market Cap
2.1B SEK
Industry
Biotechnology

Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.

DVYSR Intrinsic Value
124.21 SEK
Overvaluation 4%
Intrinsic Value
Price
D

See Also

What is Devyser Diagnostics AB's Accrued Liabilities?
Accrued Liabilities
20m SEK

Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Accrued Liabilities amounts to 20m SEK.

What is Devyser Diagnostics AB's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
38%

Over the last year, the Accrued Liabilities growth was -3%. The average annual Accrued Liabilities growth rates for Devyser Diagnostics AB have been 38% over the past three years , 38% over the past five years .

Back to Top